0001062993-20-001318.txt : 20200311 0001062993-20-001318.hdr.sgml : 20200311 20200311104217 ACCESSION NUMBER: 0001062993-20-001318 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200311 DATE AS OF CHANGE: 20200311 EFFECTIVENESS DATE: 20200311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tassili Life Science Corp. CENTRAL INDEX KEY: 0001806185 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-362494 FILM NUMBER: 20704278 BUSINESS ADDRESS: STREET 1: 366 BAY STREET, SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5H 4B2 BUSINESS PHONE: 416-270-9566 MAIL ADDRESS: STREET 1: 366 BAY STREET, SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5H 4B2 D 1 primary_doc.xml X0708 D LIVE 0001806185 Tassili Life Science Corp. 366 BAY STREET, SUITE 200 TORONTO A6 ONTARIO, CANADA M5H 4B2 416-270-9566 ONTARIO, CANADA None None Corporation true 2018 Jonathan Held 366 Bay Street Suite 200 Toronto A6 ONTARIO, CANADA M5H 4B2 Executive Officer Director Jonathan Gilbert 366 Bay Street Suite 200 Toronto A6 ONTARIO, CANADA M5H 4B2 Executive Officer Director George Scorsis 366 Bay Street Suite 200 Toronto A6 ONTARIO, CANADA M5H 4B2 Director Maghsoud Dariani 366 Bay Street Suite 200 Toronto A6 ONTARIO, CANADA M5H 4B2 Executive Officer Other Decline to Disclose 06b false 2020-02-21 false true true true true true Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions in connection with a Go Public Transaction. true Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions in connection with a Go Public Transaction. 0 300211 300211 0 Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions inconnection with a Go Public Transaction. false 10 0 0 0 false Tassili Life Science Corp. /s/ Jonathan Held Jonathan Held Chief Financial Officer 2020-03-11